These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

289 related articles for article (PubMed ID: 21383499)

  • 21. MyD88 and IFN-alphabeta differentially control maturation of bystander but not Salmonella-associated dendritic cells or CD11cintCD11b+ cells during infection.
    Tam MA; Sundquist M; Wick MJ
    Cell Microbiol; 2008 Jul; 10(7):1517-29. PubMed ID: 18363877
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ability of two Listeria monocytogenes vaccines targeting human papillomavirus-16 E7 to induce an antitumor response correlates with myeloid dendritic cell function.
    Peng X; Hussain SF; Paterson Y
    J Immunol; 2004 May; 172(10):6030-8. PubMed ID: 15128786
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enhanced HER-2/neu-specific antitumor immunity by cotransduction of mouse dendritic cells with two genes encoding HER-2/neu and alpha tumor necrosis factor.
    Chen Z; Huang H; Chang T; Carlsen S; Saxena A; Marr R; Xing Z; Xiang J
    Cancer Gene Ther; 2002 Sep; 9(9):778-86. PubMed ID: 12189528
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A multi-trimeric fusion of CD40L and gp100 tumor antigen activates dendritic cells and enhances survival in a B16-F10 melanoma DNA vaccine model.
    Gupta S; Termini JM; Rivas Y; Otero M; Raffa FN; Bhat V; Farooq A; Stone GW
    Vaccine; 2015 Sep; 33(38):4798-806. PubMed ID: 26241951
    [TBL] [Abstract][Full Text] [Related]  

  • 25. CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses.
    Rosalia RA; Cruz LJ; van Duikeren S; Tromp AT; Silva AL; Jiskoot W; de Gruijl T; Löwik C; Oostendorp J; van der Burg SH; Ossendorp F
    Biomaterials; 2015 Feb; 40():88-97. PubMed ID: 25465442
    [TBL] [Abstract][Full Text] [Related]  

  • 26. On/off TLR signaling decides proinflammatory or tolerogenic dendritic cell maturation upon CD1d-mediated interaction with invariant NKT cells.
    Caielli S; Conforti-Andreoni C; Di Pietro C; Usuelli V; Badami E; Malosio ML; Falcone M
    J Immunol; 2010 Dec; 185(12):7317-29. PubMed ID: 21078913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ligand-independent toll-like receptor signals generated by ectopic overexpression of MyD88 generate local and systemic antitumor immunity.
    Hartman ZC; Osada T; Glass O; Yang XY; Lei GJ; Lyerly HK; Clay TM
    Cancer Res; 2010 Sep; 70(18):7209-20. PubMed ID: 20823152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeted Codelivery of an Antigen and Dual Agonists by Hybrid Nanoparticles for Enhanced Cancer Immunotherapy.
    Zhang L; Wu S; Qin Y; Fan F; Zhang Z; Huang C; Ji W; Lu L; Wang C; Sun H; Leng X; Kong D; Zhu D
    Nano Lett; 2019 Jul; 19(7):4237-4249. PubMed ID: 30868883
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector.
    Williams BJ; Bhatia S; Adams LK; Boling S; Carroll JL; Li XL; Rogers DL; Korokhov N; Kovesdi I; Pereboev AV; Curiel DT; Mathis JM
    PLoS One; 2012; 7(10):e46981. PubMed ID: 23056548
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The enhanced antitumor-specific immune response with mannose- and CpG-ODN-coated liposomes delivering TRP2 peptide.
    Lai C; Duan S; Ye F; Hou X; Li X; Zhao J; Yu X; Hu Z; Tang Z; Mo F; Yang X; Lu X
    Theranostics; 2018; 8(6):1723-1739. PubMed ID: 29556352
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Toll-like receptor-dependent activation of antigen-presenting cells affects adaptive immunity to Helicobacter pylori.
    Rad R; Brenner L; Krug A; Voland P; Mages J; Lang R; Schwendy S; Reindl W; Dossumbekova A; Ballhorn W; Wagner H; Schmid RM; Bauer S; Prinz C
    Gastroenterology; 2007 Jul; 133(1):150-163.e3. PubMed ID: 17631139
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo.
    Deronic A; Nilsson A; Thagesson M; Werchau D; Enell Smith K; Ellmark P
    Cancer Immunol Immunother; 2021 Dec; 70(12):3629-3642. PubMed ID: 33948686
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Liposomes-coated gold nanocages with antigens and adjuvants targeted delivery to dendritic cells for enhancing antitumor immune response.
    Liang R; Xie J; Li J; Wang K; Liu L; Gao Y; Hussain M; Shen G; Zhu J; Tao J
    Biomaterials; 2017 Dec; 149():41-50. PubMed ID: 28992509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
    Mata M; Gerken C; Nguyen P; Krenciute G; Spencer DM; Gottschalk S
    Cancer Discov; 2017 Nov; 7(11):1306-1319. PubMed ID: 28801306
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adrenergic modulation of dendritic cell cancer vaccine in a mouse model: role of dendritic cell maturation.
    Botta F; Maestroni GJ
    J Immunother; 2008 Apr; 31(3):263-70. PubMed ID: 18317361
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antitumor Effect of KML-B-Treated Dendritic Cells via Induction of Lymphocyte Activation.
    Kim JJ; Hwang YH; Kang KY; Lee SJ; Kim JB; Choi J; Yee ST
    J Immunol Res; 2017; 2017():2471627. PubMed ID: 28634588
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant.
    Bielinska AU; Makidon PE; Janczak KW; Blanco LP; Swanson B; Smith DM; Pham T; Szabo Z; Kukowska-Latallo JF; Baker JR
    J Immunol; 2014 Mar; 192(6):2722-33. PubMed ID: 24532579
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Targeting interferon-alpha to dendritic cells enhances a CD8
    Graham JP; Authie P; Karolina Palucka A; Zurawski G
    Vaccine; 2017 Aug; 35(35 Pt B):4532-4539. PubMed ID: 28743486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. MyD88 and interferon-alpha/beta are differentially required for dendritic cell maturation but dispensable for development of protective memory against Listeria.
    Tam MA; Wick MJ
    Immunology; 2009 Nov; 128(3):429-38. PubMed ID: 20067542
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combined immunization with adjuvant molecules poly(I:C) and anti-CD40 plus a tumor antigen has potent prophylactic and therapeutic antitumor effects.
    Llopiz D; Dotor J; Zabaleta A; Lasarte JJ; Prieto J; Borrás-Cuesta F; Sarobe P
    Cancer Immunol Immunother; 2008 Jan; 57(1):19-29. PubMed ID: 17564702
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.